Daniel James George, MD

Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-4615
Email address daniel.george@duke.edu

Education and Training

  • Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
  • Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
  • M.D., Duke University, 1992

Grants

Publications

George, Daniel J., Susan Halabi, Elisabeth I. Heath, A Oliver Sartor, Guru P. Sonpavde, Devika Das, Rhonda L. Bitting, et al. “A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.” Cancer 127, no. 16 (August 15, 2021): 2954–65. https://doi.org/10.1002/cncr.33589.

PMID
33951180
Full Text

Harrison, Michael R., Brian A. Costello, Nrupen A. Bhavsar, Ulka Vaishampayan, Sumanta K. Pal, Yousef Zakharia, Heather S. L. Jim, et al. “Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).” Cancer 127, no. 13 (July 1, 2021): 2204–12. https://doi.org/10.1002/cncr.33494.

PMID
33765337
Full Text

Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.” Clin Cancer Res 27, no. 12 (June 15, 2021): 3317–28. https://doi.org/10.1158/1078-0432.CCR-20-4504.

PMID
33593885
Full Text

Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma.” Clin Cancer Res 27, no. 12 (June 15, 2021): 3503. https://doi.org/10.1158/1078-0432.CCR-21-1636.

PMID
34117029
Full Text

Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.” In Mol Cancer Res, 19:1040–50, 2021. https://doi.org/10.1158/1541-7786.MCR-20-0975.

PMID
33771885
Full Text

Scher, H. I., A. J. Armstrong, J. D. Schonhoft, A. Gill, J. L. Zhao, E. Barnett, E. Carbone, et al. “Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.” Eur J Cancer 150 (June 2021): 83–94. https://doi.org/10.1016/j.ejca.2021.02.042.

PMID
33894633
Full Text

Al Abo, Muthana, Terry Hyslop, Xiaodi Qin, Kouros Owzar, Daniel J. George, Steven R. Patierno, and Jennifer A. Freedman. “Differential alternative RNA splicing and transcription events between tumors from African American and White patients in The Cancer Genome Atlas.” Genomics 113, no. 3 (May 2021): 1234–46. https://doi.org/10.1016/j.ygeno.2021.02.020.

PMID
33705884
Full Text

Koontz, Bridget F., Karen E. Hoffman, Susan Halabi, Patrick Healy, Monika Anand, Daniel J. George, Michael R. Harrison, et al. “Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.” Int J Radiat Oncol Biol Phys 109, no. 5 (April 1, 2021): 1271–78. https://doi.org/10.1016/j.ijrobp.2020.11.059.

PMID
33259932
Full Text

Smith, Sonali M., Kerri Wachter, Howard A. Burris, Richard L. Schilsky, Daniel J. George, Douglas E. Peterson, Melissa L. Johnson, et al. “Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.” J Clin Oncol 39, no. 10 (April 1, 2021): 1165–84. https://doi.org/10.1200/JCO.20.03420.

PMID
33527845
Full Text

Laccetti, Andrew L., Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, et al. “Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.” Cancer Med 10, no. 7 (April 2021): 2341–49. https://doi.org/10.1002/cam4.3812.

PMID
33650321
Full Text

Pages